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ABSTRACT [word count – 244] 
Background. The Use of Multidrug Pill In Reducing cardiovascular Events (UMPIRE) 
trial, showed that access to a cardiovascular polypill (aspirin, statin and two blood 
pressure lowering drugs) significantly improved adherence, lowered systolic blood 
pressure (SBP) and low-density lipoprotein cholesterol (LDLc) in patients with or at 
high risk of cardiovascular disease (CVD). We aimed to analyze the within-trial cost-
effectiveness of the polypill strategy versus usual care in India. 
Methods. Relative effectiveness and costs of polypill versus usual care groups in 
UMPIRE were estimated from the health sector perspective. Only direct medical costs 
were considered. The effectiveness of the polypill was reported as a percentage increase 
in adherence and mean reductions in SBP, and LDL-c, over the 15-month trial period.  
Healthcare resource utilization and costs were collected for each patient during the 
trial. Polypill price was constructed using a range of scenarios: $0.06 - $0.94/day. The 
cost-effectiveness of the polypill was measured as the additional cost for 10% increase 
in adherence, and per unit reduction in SBP and LDL-c. 
Results. Overall, the mean cost per patient was significantly lower with the polypill 
strategy (- $203 per person, (95% CI: -286, -119, p <0.01). In scenario analyses that 
varied polypill price assumptions, incremental cost-effectiveness ratios for a polypill 
strategy ranged between cost-saving to $75 per 10% increase in adherence for polypill 
price of $0.94 per day.  
Conclusions. The polypill strategy was cost-saving compared to usual care among 
patients with or at high risk of CVD in India.   
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Main article [word count: 3519] 
Introduction 
The increased prevalence of cardiovascular disease (CVD) in developing 
countries is placing a huge burden on health care services(1-3). India, in particular, with 
a large number of individuals with hypertension, dyslipidemia, diabetes and CVD, is 
facing a significant healthcare delivery challenge(4). Patients with CVD should receive 
antiplatelet therapy and drugs to lower blood pressure (BP) and low-density 
lipoprotein cholesterol (LDLc)(5-9). However, the use of preventive cardiovascular 
medications is disappointingly low(10-12). The cost and complexity of multi-drug 
regimens impacts adversely on adherence to such treatment and therefore, on its 
effectiveness(5, 13-17). The use of a cardiovascular polypill has shown to improve 
adherence to essential cardiovascular drugs and risk factor control (18-20).   
The Use of Multidrug Pill In Reducing cardiovascular Events (UMPIRE) trial 
(21) demonstrated that a polypill based strategy improved adherence to prescribed 
therapy, and reduced BP and LDLc, compared to usual care in patients with or at high 
risk of CVD. Since the constituent drugs of the polypill used in UMPIRE are off-patent 
generics, this polypill can be manufactured at low cost. However, pharmaceutical 
companies are only likely to manufacture the polypill if the scale of prescribing 
compensates for small profit margins. Robust evidence on the cost-effectiveness of the 
polypill is therefore required to establish the polypill as part of an Indian CVD 
preventive strategy and to support the investment case for healthcare funders. India is 
estimated to have the largest number of prevalent cases of CVD in the world due to a 
high incidence rate and large population (more than 50% below the age of 25)(4). 
Further, wide variation in socio-economic status with a substantial proportion of the 
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population living below the poverty line with a predilection to have CVD at a young-age 
necessitates affordable and accessible secondary prevention treatment for CVD(22). 
Although the cost-effectiveness of pharmacological and lifestyle modification 
interventions to prevent CVD have been evaluated in decision modeling studies [few 
examples: (23-26)], the cost-effectiveness of a polypill strategy using patient outcomes 
derived from a randomized controlled trial (RCT) in an Indian context is unknown. The 
RUPEE-IND (Researching UMPIRE Processes, an Economic Evaluation in India) study 
was designed to investigate the impact of switching high risk CVD patients from usual 
care to a polypill strategy. This paper reports the “within-trial” cost-effectiveness of the 
polypill strategy relative to usual care in India. 
 
Methods 
UMPIRE trial 
The UMPIRE trial was an open label, RCT of a polypill-based strategy, 
compared to usual care, in 2004 patients with or at high risk of CVD in India, United 
Kingdom (UK), Ireland, and Netherlands. The trial was conducted between Feb 2010 
and Jan 2013 and ethics approval was obtained at each of the participating trial sites. 
Full details of the trial protocol and primary outcome results were published previously 
(21). In India, 1000 individuals aged ≥18 years and of both sexes with or at high risk of 
CVD (≥15% CVD risk over 10 years), were randomized to receive the polypill or usual 
care. Two versions of the polypill were used: Red Heart Pill (RHP) version 1: aspirin 
75mg, lisinopril 10mg, simvastatin 40mg, atenolol 50mg or RHP version 2: aspirin 
75mg, lisinopril 10mg, simvastatin 40mg, hydrochlorothiazide 12.5 mg. The polypill 
was prescribed to be taken orally, once daily and regarded as ‘background treatment’ to 
which other medications could be added to achieve physician recommended BP or 
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cholesterol targets, and/or to treat comorbidities. The RHPs were manufactured by Dr. 
Reddy’s Laboratories (Hyderabad, India) and were provided without cost to trial 
participants. 
Patient characteristics 
The trial population consisted of 501 individuals in the polypill arm and 499 
in the usual care arm in India. The baseline characteristics of the two groups were 
similar [Table 1] and were typical of CVD presentation in India, i.e. occurrence of CVD at 
a relatively young age, high prevalence of co-morbid conditions (diabetes), and the 
presence of higher CVD burden in low socio-economic strata. 
Resource utilization and costs within trial 
Costs per participant were determined from health care utilization and unit 
costs for these services. Data on treatment or cardiovascular-related use of health 
services over the study period were extracted from UMPIRE case report forms at 1 
month, 6 months, 12 months, 18 months and at the trial end. These data included: 
medication use, consultations with healthcare professionals, emergency department 
attendances, and hospitalizations related to prescribed medications.  Price estimates of 
the polypill were derived from five scenarios (Box 1). The cost of Indian rupees 3.3 
($0.06) per day used in Scenario A was an aspirational price discussed with Dr. Reddy’s 
Laboratories. This took account of potential bulk purchasing by the government drug 
procurement agencies and mass prescribing by physicians. Given the large variations in 
the market price of simvastatin (Indian rupees. 2.3 - 29.3 per pill), we constructed two 
different scenarios to account for the range of simvastatin price. Scenario B used an 
aggregate sum cost of individual constituents of polypill based on contemporary drug 
prices (simvastatin price: Indian rupees 4.0/pill) applicable to the Indian market i.e. 
Indian rupees 11.5 ($0.22) per day. Scenario C used the market price of Cadila’s 
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Polycap i.e. Indian rupees 15.4 ($0.29) per day. Scenario D was constructed using a 
similar approach as in Scenario B, but with median market price of simvastatin i.e. Indian 
rupees 18.6 was used to calculate the aggregate sum cost of polypill constituents, which 
gave Indian rupees 25.4 ($0.47) per day. Finally, in Scenario E, we doubled the price of 
the polypill as used in Scenario D to understand the maximum threshold at which the 
polypill is cost-effective i.e. Indian rupees 50 ($0.94) per day. The cost of usual care 
medications was obtained using the Pharmatrac drug database 2012. More information 
on the costing of usual care medications is provided in #Appendix 1. 
The cost of most events/hospitalizations was limited to a defined acute 
period, but stroke and renal failure events often require care for months or years after 
the initial hospitalization. Hence, for strokes we applied a cost that reflects a one-year 
period and for renal failure we applied a 6-month recurring dialysis cost that continued 
to the end of the study. A mean cost per unit was applied to resource use by each 
participant and to the clinical events reported by all study participants. Unit costs for 
healthcare services was collected from the participating trial sites using a standardized 
cost survey form (#Appendix 2).  
Within trial Cost-Effectiveness Analysis  
The analysis was carried out from a health sector perspective. Consistent 
with this perspective, we only considered direct medical costs incurred by patients and 
care providers. Indirect costs (productivity lost) and travel costs incurred by patients 
and their families/caregivers were not considered.  All analyses used the 15-month trial 
duration and no discount rate was applied. Categorical data were reported as 
frequencies (percentages) and continuous data as means with standard errors. We 
performed an intention to treat (ITT) analysis to assess both effects and costs over the 
trial duration. At the trial end, complete data on effectiveness outcomes (adherence to 
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therapy, BP and LDLc) were available for 91.1% participants. Adherence to therapy was 
defined as self-reported use of antiplatelet, statin, and ≥2BP-lowering drugs, for at least 
4 days during the week preceding the visit at baseline and at the trial end (21). The 
EQ5D questionnaire was applied to assess quality of life and we report the Visual 
Analogue Scale (VAS) results between the two groups because currently there is no 
value set available to calculate EQ5D utility scores in India. For the base-case ITT 
analysis, we imputed missing data using the last observation carried forward method. 
Incremental cost-effectiveness ratios (ICERs) were calculated as the difference in costs 
divided by the difference in effects between the polypill and usual care group. The ICER 
is a summary measure indicating the cost-effectiveness of an intervention compared to 
an alternative. In situations where the intervention costs are higher than usual care, the 
ICER represents the additional costs per additional unit of benefit. Where an 
intervention or usual care is dominant (more effective and less expensive than the 
comparator), the ICER is negative and is not meaningful (27). The cost-effectiveness 
analysis (CEA) results are reported as incremental cost per 10% increase in adherence 
and per unit reduction in SBP (mmHg) and LDLc (mg/dl). We report ICERs for the 
different polypill price scenarios, where appropriate, and do not report negative ICERs. 
Bootstrap sampling was used to estimate uncertainty around the cost and effectiveness 
estimates (28, 29). CEA results from bootstrap replications were plotted on a cost-
effectiveness plane and using a cost-effectiveness acceptability curve (CEAC) against a 
range of willingness to pay (WTP) values (30). All statistical analyses were completed 
using Microsoft Office Excel 2007, and STATA (version 12.0 SE; StataCorp, TX, USA). 
Sensitivity analyses  
We conducted several deterministic sensitivity analyses to examine 
uncertainty in the key input variables (e.g. effectiveness, cost of drug), which could 
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potentially influence the ICER. Further, in a multivariable sensitivity analysis, we 
simulated the best (and worst) case scenarios using the maximum effectiveness of the 
polypill, minimum cost of the polypill, minimum cost of healthcare visits and minimum 
cost of hospitalizations/events. Minimum/maximum cost was defined by lower/upper 
bound of 95% confidence interval (CI). 
Sub-group analyses 
Several subgroups were analyzed to explore potential cost differences: 
established CVD versus high CVD risk patients, age, gender, education strata, income 
class, employment status, public vs. private health setting, and adherence to prescribed 
therapy, as defined in the UMPIRE trial (31).  
 
Results 
Effectiveness of polypill  
At 15 months, compared to usual care, adherence was significantly greater 
with the polypill strategy compared to usual care (85% vs. 68%, p<0.01), with 
statistically significant improvement in SBP (3.3 units [mmHg] greater reduction, 
p=0.004), and LDL-cholesterol (12.3 units [mg/dl] greater reduction, p <0.01). At trial 
end, the mean EQ5D-VAS score was 75.0 vs. 73.4 in the polypill arm vs. usual care 
(p=0.08). Total number of people with serious adverse events reported were 26 vs. 15 
with polypill strategy vs. usual care (p=0.07) [Table 2]. 
Medication, healthcare visits and hospitalization costs 
Compared to the usual care, the cost of medications per person was 
significantly lower with the polypill strategy at 15 months (cost difference of $242.8 per 
person, 95% CI: $-318.7, $-166.7, p<0.01).  There was no significant difference in costs 
associated with out-patient healthcare visits between the two treatment strategies. 
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However, the costs of hospitalizations were significantly higher with the polypill 
strategy compared to usual care (cost difference of $39.8 per person, 95% CI: $4.7, 
$74.7, p=0.03). Overall, the average cost, summing the cost of medications, out-patient 
healthcare visits and hospitalizations per patient, was significantly lower with the 
polypill strategy compared to usual care (cost difference of $202.9 per person, 95% CI: 
$-286.4, $-119.4, p < 0.01) [Table 3].    
Cost effectiveness 
In scenarios A-D, we found that the polypill strategy dominated usual care 
(lower cost and greater benefits with the polypill strategy) [Tables 4a-4c]. Whereas, in 
scenario E (polypill price: $0.94/day), the ICER for the polypill strategy was: $75.0 per 
10% increase in adherence; and $64.7 and $21.0 per unit reduction in SBP and LDLc, 
respectively (Tables 4a-4c). Using a conservative estimate of CVD prevalence in India 
(37 million cases) (22, 32, 33), and based on varied polypill price assumptions ($0.06 - 
$0.94 per day), a polypill-based strategy could potentially result in net saving of $259 - 
$6096 per million population in India (Tables 4a – 4c). 
The bootstrapped CEA results for primary outcomes - adherence, SBP and 
LDLc - plotted on the cost-effectiveness plane are presented in Online Figure 1 for all 
five scenarios of cost of polypill. In scenarios A-C, the cost-effectiveness planes 
demonstrate a high degree of certainty in the dominance of the polypill, as reflected by 
almost all of the sampled cost-effectiveness point estimates falling in the bottom right 
(South East) quadrant. This suggests that the polypill strategy is highly likely to be more 
effective and cheaper than usual care, and therefore, is the treatment of choice for CVD 
management. Only in scenario E, where we assumed the cost of polypill to be double 
that of the sum cost of its constituent drugs ($0.94/day), do most of the 
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cost/effectiveness points fall in top right (North East) quadrant for polypill strategy, 
indicating a greater benefit at higher cost.  
CEACs for the different polypill price assumptions are presented in Online 
Figure 2. For scenario A - C the polypill remained consistently cost-effective across 
almost all bootstrapped iterations and at all WTP values. This suggests a very high 
probability that the polypill would be both cost-effective and cost-saving at prices of up 
to $0.29 (INR. 15.4) per day. At higher prices (Scenario D and E), as the WTP per unit of 
effectiveness increases, so does the estimated probability that the polypill is cost-
effective. In Scenario D: at $0 WTP for a unit of effect (10% increase in adherence) there 
is an 80% probability that the polypill would be cost-effective. The probability rises to 
about 100% for WTP above $800 per 10% increase in adherence. Similarly, for scenario 
E: at $800 WTP for a 10% increase in adherence, there is an 80% probability that the 
polypill would be cost-effective. However, the probability rises to 100% at the WTP 
above $1200 per 10% increase in adherence. 
Sensitivity analysis results 
Our cost-effectiveness results were robust to several sensitivity analyses. 
The unit cost of healthcare visits had minimal impact on cost-effectiveness estimates, 
whereas the ICER was most sensitive to the effectiveness and cost of polypill. In all one-
way sensitivity analyses and best-case scenarios usual care therapy was dominated by 
the polypill strategy, confirming that the polypill is a cost-effective option in the Indian 
context (Online Table 1). In the worst case-scenario, the ICERs for the 10% increase in 
adherence, per unit reduction in LDLc and SBP was $373, $504, and $202, respectively. 
Subgroup analyses results 
Across all major sub-groups, the participants in the polypill group incurred 
significantly less cost, compared to the usual care group (p<0.01). Increased cost 
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savings were particularly noted in people aged ≥ 55 years, males, and patients at high 
risk of cardiovascular disease. Individuals with co-morbid conditions such as diabetes 
and those with high adherence rates had two times greater cost savings with the 
polypill strategy vs. usual care. [Online Table 2].  
 
Discussion 
This trial-based cost effectiveness analysis found the polypill strategy to be 
cost-effective with greater clinical benefits (improved adherence, lower SBP and LDLc) 
at lower healthcare cost, compared to usual care in patients with or at high risk of CVD 
in India. The results were largely driven by the overall net savings in the medication 
cost with the polypill strategy. The polypill strategy had a very high probability of being 
cost-saving up to a maximum price of $0.54 per day. At a higher price (>$0.54/pill) the 
polypill may still be cost-effective depending on decision makers’ maximum willingness 
to pay for a unit of health benefit.  
RUPEE is the first study to report the cost-effectiveness of a cardiovascular 
polypill strategy for secondary prevention of CVD in India. The main strength of this 
analysis is that it uses patient level data from a well-designed RCT. The trial followed a 
standardized protocol and measurement tools across 28 participating sites in India to 
produce strong evidence on the effectiveness of a polypill compared to usual care. Our 
CEA results are robust to a number of scenario, subgroup and sensitivity analyses.  
The CEA has limitations. The analysis is based on the prices of drugs as they 
stood at the end of the trial in 2012. The results may not hold if there are future price 
changes in the cost of preventive CVD medicines. However, we have conducted a range 
of sensitivity analysis around the price of the medication, so this should capture any 
future changes in the price. The study assumed the market price of a polypill based on 
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different pricing strategies, which is helpful to understand the threshold at which the 
polypill is or is not considered cost-effective. The current study could not estimate the 
likely effect of long-term polypill-based care on cardiovascular events for several 
reasons – there were relatively few events, follow-up was short considering there is a 
lag-time of a year or so for the full extent of cardiovascular benefits to appear (e.g., for 
cholesterol lowering effect (34-36)), and also patients in both groups are generally 
treated more intensively than average in a clinical trial setting.  Furthermore, in an 
unblinded trial such as this one, it remains possible that differential treatment and/or 
reporting was provided to the participants in the polypill group. 
Multidrug regimens (aspirin, beta-blockers, ACEI, or lipid-lowering drugs) for 
secondary prevention of CVD have been shown to be cost-effective according to World 
Health Organization (WHO) standards (37). But, a polypill strategy would be more cost-
effective than usual care. Previous studies have modelled CVD reduction on the 
assumption of aspirin adherence and sustained BP and LDL-c reductions and the 
established relationships between these risk factor changes and CVD events in past 
trials (23, 24, 37, 38). A decision modelling study conducted within the Dutch health 
system found that the polypill would be a cost-effective strategy in individuals with a 10 
year cardiovascular (CV) risk of 7.5% (26). Another CEA of the polypill in a high CV risk 
population (≥15% CV risk over 10 years) in Latin America performed using a Markov 
model, reported that the provision of a polypill to those with or at high risk of CVD 
would yield an acceptable ICER: $34–$36 per QALY (38).  
A recent study in India evaluated the cost-effectiveness of policies to expand 
coverage, access and use of CVD prevention drugs including a polypill strategy in 
patients with acute myocardial infarction for secondary prevention of CVD (39). This 
study found that a policy to expand access to the polypill is the most cost-effective 
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option when compared to aspirin, statins and BP lowering drugs prescribed separately 
[ICER: $1690 per disability-adjusted life years (DALYs) averted]. However, this study 
did not incorporate the impact of improved adherence to therapy due to the 
introduction of polypill and did not consider the cost of hospitalizations due to polypill 
treatment in their analysis (39). More recently, a Markov model based CEA 
demonstrated the benefits of improved adherence with a cardiovascular polypill versus 
multiple monotherapy for the secondary prevention of CVD in the UK and Spain (24, 
40). The UK study found that an additional 6.7% CVD events can be prevented for 10% 
increase in adherence and ICERs ranged between cost-saving and £21,430 [$27,319.4] 
per QALY gained (24). Our study results are consistent with a favorable ICER (across a 
wide range of willingness to pay threshold) for clinical outcomes such as adherence to 
medications and improvement in SBP and LDLc. However, as our cost-effectiveness 
estimates are generated from within the time period of the UMPIRE trial, further long-
term studies or modelled evaluations could demonstrate benefits in terms of CVD 
events averted and quality adjusted life years gained with this polypill based strategy 
versus usual care. However, such long-term extrapolations from the present study, 
where we found the polypill strategy to be dominant, is unlikely to alter the existing 
conclusions that there is a strong investment case for such a strategy.   
The disparity in the use of cardio-protective drugs between countries is 
extremely high (10, 11, 41). Much of the difference in the use of CVD medications is 
explained by a strong positive correlation with a countries’ GDP and health 
expenditures per capita(42). This is particularly seen in the use of statins, which are 
more expensive and are used relatively infrequently in South Asia but are the most used 
drug in high-income countries (10, 42). Apparently, the main barrier to the use of 
preventive cardiovascular drug is high out-of-pocket health expenditures. However, the 
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use of aspirin, an inexpensive drug, is also low. Thus, a possible barrier to secondary 
prevention could be related to adherence to multi-medication therapy. In addition, a 
sizeable proportion of the Indian population live below the poverty line and treatment 
for CVD can incur catastrophic health expenditures(43, 44). It is thus, important to 
advocate for low-cost affordable treatment options for chronic care of CVD. The polypill 
has the advantage of being one pill instead of four, making it a less complex regimen 
which could promote more widespread use and greater adherence(45-47). The 
simplified treatment regimen and lower cost of the polypill relative to usual care further 
drives the polypill’s dominance in our CEA. It is important to note that the polypill was 
found to be effective and cost-effective, in improving adherence and lowering SBP and 
LDLc, despite using simvastatin, whereas the usual care strategy used recent and more 
potent statins [in the Indian pharmaceutical market, simvastatin appears to be more 
expensive than atorvastatin]. Therefore, the impact of a polypill could be greater with 
the use of more potent and less expensive statins.  
 
Conclusion 
In line with the WHO “25x25” goal and recognizing the urgent need to 
identify and promote the most cost-effective interventions for CVD prevention, our 
findings offer a cost-effective option of delivering and improving care for CVD patients 
in low-resource settings with a polypill strategy. A low-cost polypill would improve the 
access, availability and affordability of CVD prevention treatment for millions of people 
living with cardiovascular disease globally.  
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Tables  
Table 1: Baseline characteristics of UMPIRE trial participants (India, N=1000) 
Characteristics Polypill (n=501) Usual care (n=499) 
Age, mean (SD) 57.7 (10.3) 57.3 (10.9) 
Males (%) 77.8 78.7 
Self-reported medical history (%)   
Established CVD 92 92 
Coronary artery disease  83 81 
Cerebrovascular disease  13.0 12.6 
Diabetes  32.0 34.0 
Family history of CVD  11.6 11.4 
Ever smoker (%) 32.0 31.0 
Current alcohol use (%) 7.6 7.2 
Systolic Blood pressure (mmHg), mean 
(SD) 
136.0 (23.3) 136.1 (22.5) 
Diastolic Blood pressure (mmHg), mean 
(SD) 
78.5 (13.8) 78.2 (12.6) 
Total cholesterol (mg/dl) 153.6 (36.5) 165.3 (43.3) 
HDLc (mg/dl), mean (SD) 40.8 (8.6) 40.9 (8.4) 
LDLc (mg/dl), mean (SD) 85.4 (30.3) 96.0 (37.9) 
Triglycerides (mg/dl), mean (SD) 145.0 (84.4) 149.7 (85.7) 
Serum Creatinine, mean (SD) 1.1 (0.3) 1.0 (0.3) 
Fasting blood glucose (mg/dl), mean (SD) 115.7 (46.6) 119.1 (47.5) 
Education categories (%) 
  Post-graduate degree 4.4 5.4 
Undergraduate degree 12.2 14.5 
Secondary school 36.0 36.0 
Primary school 30.7 34.7 
None 11.6 12.7 
Employment status, (%) 
  Full-time 28.0 28.0 
Part-time 9.4 9.2 
Retired / unemployed 62.5 62.4 
Total household income per month (INR), 
(%) 
  <3000 28.0 32.0 
3000 - 10,000 41.0 36.0 
10,001 - 50,000 14.6 18.5 
>50,000 0.8 0.6 
Don't know / Didn't respond 15.6 13.5 
*Abbreviations: CVD – cardiovascular disease, n – number of participants, mg/dl – milligrams per decilitre, mmHg – 
millimetre of mercury, SD – standard deviation, HDLc – high density lipoprotein cholesterol, LDLc – low density 
lipoprotein cholesterol, INR. – Indian rupees 
**Standard deviations reported within parenthesis in the above table. 
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Box 1: Indicative price of polypill based on varied pricing strategies (costs, 2012≠) 
Scenario Source of information Unit price in 
INR per day 
Unit price in 
$ per day 
A As recommended in the UMPIRE protocol 3.3 0.06 
B Aggregate sum cost of individual constituents of 
polypill (based on contemporary drug prices 
applicable to Indian pharmaceutical market)* 
  
 RHP1c   
 Simvastatin 40mg (Simvas 40mg) 4.7 0.09 
 Aspirin 75 mg 0.3 0.00 
 Lisinopril 10mg (Lipril 10mg) 3.4 0.06 
 Atenolol 50mg (ATEN 50mg) 3.2 0.06 
 Aggregate sum cost 11.5 0.22 
 RHP2c   
 Simvastatin 40mg (Simvas 40mg) 4.7 0.09 
 Aspirin 75 mg 0.3 0.00 
 Lisinopril 10mg (Lipril 10mg) 3.4 0.06 
 Hydrochlorothiazide 12.5mg (Dithiazide 12.5mg) 2.0 0.04 
 Aggregate sum cost 10.4 0.19 
C Equivalent to market price of Cadila's Polycap 15.4 0.29 
D Aggregate sum cost of individual constituents of 
polypill (based on median market price for 
simvastatin) ** 
  
 RHP1c   
 Simvastatin 40mg (Simvas 40mg) 18.6 0.35 
 Aspirin 75 mg 0.3 0.00 
 Lisinopril 10mg (Lipril 10mg) 3.4 0.06 
 Atenolol 50mg (ATEN 50mg) 3.2 0.06 
 Aggregate sum cost 25.4 0.48 
 RHP2c   
 Simvastatin 40mg (Simvas 40mg) 18.6 0.35 
 Aspirin 75 mg 0.3 0.00 
 Lisinopril 10mg (Lipril 10mg) 3.4 0.06 
 Hydrochlorothiazide 12.5mg (Dithiazide 12.5mg) 2.0 0.04 
 Aggregate sum cost 24.3 0.45 
E Twice the price of aggregate sum cost of polypill 
constituents 
50.0 0.94 
UMPIRE = Use of Multidrug Pill in Reducing cardiovascular Events trial, INR = India Rupee, USD = United 
States Dollar 
*Scenario B - Source, Pharmatrac database, 2012: Lupin - starstat (simvastatin 40mg) - INR 4.71 (or $0.09) 
per pill 
**Scenario D - Source, Pharmatrac database, 2012: Median market price of simvastatin 40mg was used few 
examples: Zocor (MSD) INR. 20.32 (or $ 0.38)/pill, SIMVOTIN (Ranbaxy) INR. 32.25 (or $0.60) / pill, ZOSTA 
(USV) - INR. 17.15 (or $ 0.32)/pill 
 
≠conversion rate used: 1US$ = 53.4 INR. https://data.oecd.org/conversion/exchange-rates.htm#indicator-
chart conversion rate (2012)  
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Table 2: Summary of UMPIRE Trial results at the end of study: India 
 
Outcomes (Primary end points) 
Polypill Usual care 
Treatment effect 
(relative risk for 
adherence, mean 
difference for SBP 
& LDLc), (95% CI) P value 
(N = 501) (N = 499) 
  
Self-reported use of antiplatelet, statin 
and combination (>=2) blood pressure 
lowering therapy at the end of study 
387/457(0.85) 310/454(0.68) 1.24 (1.15, 1.34) <.001 
Systolic blood pressure (mmHg), SD 123.6 (19.2) 126.9 (18.1) -3.3 (-8.5, -1.9) 0.004 
LDL cholesterol (mg/dl), SD 81.4 (27.9) 93.74 (36) -12.3 (-21.2, -3.49) <0.01 
Secondary end point 
    
Health related quality of life (EQ-VAS), 
SD 
75 (13.7) 73.4 (13.9) 1.6 ( -0.19 ; 3.4) 0.08 
Serious adverse events (total = 41) 26 15 
 
0.07 
Abbreviations: N-number of participants, SBP – systolic blood pressure, LDLc – low density lipoprotein cholesterol, 
QALYs – quality adjusted life years, EQ-VAS – European quality of life – Visual Analogue Scale, mmHg- millimetre per 
mercury, mg/dl – milligram per decilitre, CI – Confidence Interval, SD- Standard Deviation  
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Table 3: Summary of mean resource use and cost per patient [Within-trial cost analysis] - US$, 
2012 
Item Polypill  Usual care Difference   
  Cost[mean] S.E Cost[mean] S.E Cost [mean] 95% CI p-value 
Medication cost 
(total) 
213.6 20.9 456.3 32.7 -242.8 (-318.7, -166.7) <0.01 
CVD medicines cost 70.2 3.2 240.8 5.0 -170.6 (-182.3, -159.0) <0.01 
Other medicines cost 143.7 20.6 214.1 31.4 -70.3 (-144.0, 3.2) 0.06 
Healthcare visits 
cost (total) 
9.8 1.1 10.1 1.1 -0.3 (-3.3, 2.8) 0.8 
Hospitalizations 
cost (total) 
55.7 16.6 16.0 6.5 39.8 (4.7, 74.7) 0.03 
CVD events cost 53.6 16.6 12.7 6.3 40.9 (6.1, 75.7) 0.02 
Other events cost 2.1 1.0 3.3 1.6 -1.2 (-4.8, 2.4) 0.5 
Overall mean cost 
per patient 
279.5 26.6 482.4 33.3 -202.9 (-286.4, -119.4) <0.01 
*SE: standard error, CVD – cardiovascular disease, CI – Confidence Interval, US$ - united states 
dollar 
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Table 4.a. Within trial costs, effects and cost-effectiveness of polypill strategy versus usual care 
(10% increase in adherence), US$, 2012 
Adherence 
outcome 
Cost 
($) 
Incr. 
cost 
($) 
Effect (% 
Increase in 
adherence) 
Incr. 
effect 
ICER - 10% 
increase in 
adherence 
Total cost per 
million popn 
($) (India) 
Cost-saving per 
million popn 
($) (India) 
Scenario A  
(PP = $0.062 
(INR.3.3)/day) 
       Polypill 279.1 -203.3 25.3 20.7 dominant 408.2 3472.0 
Usual care 482.4 
 
4.6 
  
3880.1 
 
        Scenario B  
(PP = $0.22 
(INR.11.55)/day) 
       Polypill 343.9 -138.5 25.3 20.7 dominant 502.9 3377.2 
Usual care 482.4 
 
4.6   3880.1  
   
     
Scenario C  
(PP = $0.29 
(INR.15.4)/day) 
  
     
Polypill 372.0 -110.4 25.3 20.7 dominant 544.0 3336.1 
Usual care 482.4 
 
4.6   3880.1  
   
     
Scenario D  
(PP = $0.47 (INR. 
25)/day) 
  
     
Polypill 445.7 -36.7 25.3 20.7 dominant 651.8 3228.3 
Usual care 482.4 
 
4.6   3880.1  
   
     
Scenario E  
(PP = $0.94 
(INR.50)/day) 
  
     
Polypill 637.6 155.2 25.3 20.7 75.0 932.5 2947.7 
Usual care 482.4   4.6   3880.1  
*Total cost per million population was calculated based on a conservative estimate of prevalence of CVD in India i.e. 35 
million CHD and 2 million stroke cases (source: Circulation, 2016, and National Commission on Macroeconomics, 2005); 
Abbreviation – PP – Polypill; SBP – systolic blood pressure, CHD – Coronary heart disease, CVD – cardiovascular disease, 
$ - United States dollar, INR. – Indian rupees, Incr. - Incremental, popn. – population, ICER – incremental cost-
effectiveness ratio 
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Table 4.b. Within trial costs, effects and cost-effectiveness of polypill strategy versus usual care 
(Systolic blood pressure (SBP) outcome measure), US$, 2012 
SBP outcome 
Cost 
($) 
Incr. 
cost 
($) 
Effect 
(SBP 
reduction) 
Incr. 
effect 
ICER 
 
Total cost ($) 
per million 
popn (India) 
Cost-saving 
($) per million 
popn (India) 
Scenario A  
(PP = $0.062 
(INR.3.3)/day) 
       Polypill 279.1 -203.3 7.9 2.4 dominant 1307 1938 
Usual care 482.4 
 
5.5 
 
 3245 
 
     
 
  Scenario B  
(PP = $0.22 
(INR.11.55)/day) 
    
 
  Polypill 343.9 -138.5 7.9 2.4 dominant 1611 1634 
Usual care 482.4 
 
5.5 
 
 3245 
 
     
 
  Scenario C  
(PP = $0.29 
(INR.15.4)/day) 
    
 
  Polypill 372.0 -110.4 7.9 2.4 dominant 1742 1503 
Usual care 482.4 
 
5.5 
 
 3245 
 
     
 
  Scenario D  
(PP = $0.47 (INR. 
25)/day) 
    
 
  Polypill 445.7 -36.7 7.9 2.4 dominant 2087 1158 
Usual care 482.4 
 
5.5 
  
3245 
 
        Scenario E  
(PP = $0.94 
(INR.50)/day) 
       Polypill 637.6 155.2 7.9 2.4 64.7 2986 259 
Usual care 482.4   5.5     3245   
*Total cost per million population was calculated based on a conservative estimate of prevalence of CVD in India i.e. 35 
million CHD and 2 million stroke cases (source: Circulation, 2016, and National Commission on Macroeconomics, 2005); 
Abbreviation – PP – Polypill; SBP – systolic blood pressure, CHD – Coronary heart disease, CVD – cardiovascular disease, 
$ - United States dollar, INR. Indian rupees, Incr. - Incremental, popn. – Population, ICER – incremental cost-effectiveness 
ratio 
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Table 4.c. Within trial costs, effects and cost-effectiveness of polypill strategy versus usual care 
(Low density lipoprotein cholesterol (LDLc) outcome measure), US$, 2012 
 
LDLc outcome 
Cost 
($) 
Incr. 
cost ($) 
Effect 
(LDLc 
reduction) 
Incr. 
effect ICER 
Total cost per 
million popn 
($) (India) 
Cost-saving per 
million popn 
($) (India) 
Scenario A  
(PP = $0.06 
(INR. 3.3)/day) 
       Polypill 279.1 -203.3 9.9 7.4 dominant 1043 6096 
Usual care 482.4 
 
2.5 
 
 7139 
 
     
 
  Scenario B  
(PP = $0.22 
(INR. 11.5)/day) 
    
 
  Polypill 343.9 -138.5 9.9 7.4 dominant 1285 5854 
Usual care 482.4 
 
2.5 
 
 7139 
 
     
 
  Scenario C  
(PP = $0.29 
(INR. 15.4)/day) 
    
 
  Polypill 372.0 -110.4 9.9 7.4 dominant 1390 5749 
Usual care 482.4 
 
2.5 
 
 7139 
 
     
 
  Scenario D  
(PP = $0.47 
(INR. 25)/day) 
    
 
  Polypill 445.7 -36.7 9.9 7.4 dominant 1666 5474 
Usual care 482.4 
 
2.5 
 
 7139 
 
        Scenario E  
(PP = $0.94 
(INR.50)/day) 
       Polypill 637.6 155.2 9.9 7.4 21.0 2383 4756 
Usual care 482.4   2.5     7139   
 *Total cost per million population was calculated based on a conservative estimate of prevalence of CVD in India i.e. 35 
million CHD and 2 million stroke cases (source: Circulation, 2016, and National Commission on Macroeconomics, 2005); 
Abbreviation – PP – Polypill; SBP – systolic blood pressure, CHD – Coronary heart disease, CVD – cardiovascular disease, 
$ - United States dollar, INR. Indian rupees, Incr. - Incremental, popn. – population, ICER – incremental cost-effectiveness 
ratio 
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